AU2019205774B2 - Treatment of myopic progression - Google Patents

Treatment of myopic progression Download PDF

Info

Publication number
AU2019205774B2
AU2019205774B2 AU2019205774A AU2019205774A AU2019205774B2 AU 2019205774 B2 AU2019205774 B2 AU 2019205774B2 AU 2019205774 A AU2019205774 A AU 2019205774A AU 2019205774 A AU2019205774 A AU 2019205774A AU 2019205774 B2 AU2019205774 B2 AU 2019205774B2
Authority
AU
Australia
Prior art keywords
copper
composition
eye
containing agent
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019205774A
Other languages
English (en)
Other versions
AU2019205774A1 (en
Inventor
Balamurali K. Ambati
Randon Michael BURR
Sarah A. MOLOKHIA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Utah Research Foundation Inc
Original Assignee
University of Utah Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Utah Research Foundation Inc filed Critical University of Utah Research Foundation Inc
Publication of AU2019205774A1 publication Critical patent/AU2019205774A1/en
Priority to AU2024278182A priority Critical patent/AU2024278182A1/en
Application granted granted Critical
Publication of AU2019205774B2 publication Critical patent/AU2019205774B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2019205774A 2018-01-05 2019-01-07 Treatment of myopic progression Active AU2019205774B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2024278182A AU2024278182A1 (en) 2018-01-05 2024-12-06 Treatment of myopic progression

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862614230P 2018-01-05 2018-01-05
US62/614,230 2018-01-05
PCT/US2019/012501 WO2019136358A1 (en) 2018-01-05 2019-01-07 Treatment of myopic progression

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2024278182A Division AU2024278182A1 (en) 2018-01-05 2024-12-06 Treatment of myopic progression

Publications (2)

Publication Number Publication Date
AU2019205774A1 AU2019205774A1 (en) 2020-08-06
AU2019205774B2 true AU2019205774B2 (en) 2025-01-02

Family

ID=67143996

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019205774A Active AU2019205774B2 (en) 2018-01-05 2019-01-07 Treatment of myopic progression
AU2024278182A Pending AU2024278182A1 (en) 2018-01-05 2024-12-06 Treatment of myopic progression

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2024278182A Pending AU2024278182A1 (en) 2018-01-05 2024-12-06 Treatment of myopic progression

Country Status (8)

Country Link
US (2) US11524032B2 (enExample)
EP (1) EP3735209A4 (enExample)
JP (3) JP7324208B2 (enExample)
KR (2) KR20250109788A (enExample)
CN (1) CN112105320A (enExample)
AU (2) AU2019205774B2 (enExample)
CA (1) CA3087622A1 (enExample)
WO (1) WO2019136358A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4324454A3 (en) * 2016-03-08 2024-05-01 University of Utah Research Foundation Cross-linking agents and associated methods
KR20250109788A (ko) 2018-01-05 2025-07-17 유니버시티 오브 유타 리서치 파운데이션 근시 진행의 치료
AU2020311441B2 (en) * 2019-07-11 2025-12-04 University Of Utah Research Foundation Multi-agent ocular formulations and treatment methods
TW202245810A (zh) * 2021-02-01 2022-12-01 美商艾維娜傳送系統公司 散光之治療
TW202302121A (zh) * 2021-02-11 2023-01-16 猶他大學研究基金會 近視之治療
CN115282349A (zh) * 2022-07-05 2022-11-04 复旦大学附属眼耳鼻喉科医院 一种有利于改善孟加拉玫瑰红-绿光角膜胶原交联技术中cct降低的角膜交联试剂
CN115386105B (zh) * 2022-08-26 2024-03-22 昆明理工大学 多重酶活性纳米酶荧光水凝胶的制备方法及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060276777A1 (en) * 2005-04-08 2006-12-07 Coroneo Minas T Corneal shaping
WO2017155580A1 (en) * 2016-03-08 2017-09-14 University Of Utah Research Foundation Cross-linking agents and associated methods

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3416530A (en) * 1966-03-02 1968-12-17 Richard A. Ness Eyeball medication dispensing tablet
WO1991004741A1 (fr) * 1989-09-27 1991-04-18 Moskovsky Nauchno-Issledovatelsky Institut Glaznykh Boleznei Imeni Gelmgoltsa Composition de traitement de la myopie evolutive
EP1159941A3 (en) * 1991-10-15 2003-09-17 Ista Pharmaceuticals, Inc. Formulations for use in enzyme-orthokeratology
CN1047523C (zh) * 1993-11-23 1999-12-22 华中理工大学 一种防治近视的滴眼液
DE69928087D1 (de) * 1998-03-09 2005-12-08 Ista Pharmaceuticals Inc Verwendung von glyceraldehyde als hornhaut härtungsmitteln
US6231889B1 (en) * 1998-09-21 2001-05-15 Chronorx, Llc Unit dosage forms for the treatment of herpes simplex
CA2443244A1 (en) * 2001-04-13 2002-10-24 Incyte Genomics, Inc. Enzymes
EP1592435A4 (en) * 2002-12-20 2008-01-23 Chakshu Res Inc EYE FORMULATION FOR THE PREVENTION AND TREATMENT OF EYE DRESS
CN1518981A (zh) * 2003-07-23 2004-08-11 复旦大学附属眼耳鼻喉科医院 一种治疗近视的外用滴眼制剂
MXPA03011987A (es) * 2003-12-19 2005-06-23 Osio Sancho Alberto Metodo para el tratamiento de la presbicia induciendo cambios en el poder y fisiologia corneal.
EP1814540A2 (en) 2004-11-16 2007-08-08 Nu-Tein Co., Inc. Compositions useful to treat ocular neovascular diseases and macular degeneration
US20080014247A1 (en) 2006-06-30 2008-01-17 Nucryst Pharmaceuticals Metal-containing formulations and methods of use
EP2999471B1 (en) * 2013-05-19 2020-12-16 Avedro, Inc. Systems, methods, and compositions for cross-linking
RU2635185C2 (ru) 2013-12-17 2017-11-09 Иван Дмитриевич Захаров Фармацевтический препарат для профилактики и лечения прогрессирующей близорукости
US10426663B2 (en) * 2014-04-09 2019-10-01 Universität Leipzig Device for a medical treatment of a sclera
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
BR112017021374A2 (pt) * 2015-04-09 2018-07-03 Laboratori Baldacci S.P.A. ácido pirrolidona carboxílico (pca) para uso oftálmico
US10010502B2 (en) 2015-05-19 2018-07-03 Amorphex Therapeutics Llc Device that delivers a sustained low-dose of a myopia-suppressing drug, while preserving pupillary function and accommodation
WO2019104191A1 (en) 2017-11-21 2019-05-31 Sydnexis, Inc. Ophthalmic composition and delivery device thereof
KR20250109788A (ko) 2018-01-05 2025-07-17 유니버시티 오브 유타 리서치 파운데이션 근시 진행의 치료
AU2020311441B2 (en) * 2019-07-11 2025-12-04 University Of Utah Research Foundation Multi-agent ocular formulations and treatment methods
TW202245810A (zh) * 2021-02-01 2022-12-01 美商艾維娜傳送系統公司 散光之治療
TW202302121A (zh) * 2021-02-11 2023-01-16 猶他大學研究基金會 近視之治療

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060276777A1 (en) * 2005-04-08 2006-12-07 Coroneo Minas T Corneal shaping
WO2017155580A1 (en) * 2016-03-08 2017-09-14 University Of Utah Research Foundation Cross-linking agents and associated methods

Also Published As

Publication number Publication date
US20230256012A1 (en) 2023-08-17
JP2025111434A (ja) 2025-07-30
JP2021509902A (ja) 2021-04-08
EP3735209A1 (en) 2020-11-11
US11524032B2 (en) 2022-12-13
EP3735209A4 (en) 2021-09-08
AU2024278182A1 (en) 2025-01-02
JP7655988B2 (ja) 2025-04-02
WO2019136358A1 (en) 2019-07-11
CA3087622A1 (en) 2019-07-11
KR20200118426A (ko) 2020-10-15
JP7324208B2 (ja) 2023-08-09
CN112105320A (zh) 2020-12-18
JP2023153905A (ja) 2023-10-18
KR20250109788A (ko) 2025-07-17
KR102831250B1 (ko) 2025-07-08
US20210060059A1 (en) 2021-03-04
AU2019205774A1 (en) 2020-08-06

Similar Documents

Publication Publication Date Title
US20230256012A1 (en) Treatment of myopic progression
AU2023202236B2 (en) Cross-linking agents and associated methods
AU2020311441B2 (en) Multi-agent ocular formulations and treatment methods
KR20240021734A (ko) 근시의 치료
HK40107891A (en) Cross-linking agents and associated methods

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)